Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 13, 2017

View Archived Issues

Ionis Pharmaceuticals licenses drug to Dynacure

EMA's CHMP supports expanding Nplate indication

Preclinical evaluation of selective ATM kinase AZD-1390 inhibitor for treatment of glioblastoma

EMA committee recommends expanding approval of Orkambi

Discovery of novel ERK1/2 inhibitors with robust antitumor activity in vivo

CHMP issues positive opinion on Avastin biosimilar ABP-215

Neurimmune, Ono Pharmaceutical to collaborate on antibodies for neurodegenerative diseases

Devonian Health Group begins phase IIa study of Thykamine in atopic dermatitis

Benralizumab obtains positive opinion in E.U.

FDA accepts for review Sunovion's NDA for dasotraline

EMA committee confirms refusal of Fanaptum MAA

CFTR potentiator GLPG-2451 appears safe in first-in-human study

FDA expands approval of Bristol-Myers Squibb's Sprycel

Phase III results reported for ozanimod in relapsing MS

EMA grants PRIME designation to Mereo's BPS-804

Pfizer initiates phase I study of pegfilgrastim biosimilar PF-06881894

Wound healing improved with SNF-472 in hemodialysis patients with calciphylaxis

PharmaMar expects negative feedback for Aplidin MAA from EMA committee

University of Massachusetts divulges rAAV vectors encoding aspartoacylase

Novel Bcl-2-targeting drugs created at BioVentures

Dana-Farber Cancer Institute presents new anti-EGFR proteolysis-targeting chimera compounds

Baruch S. Blumberg Institute identifies novel glucosidase inhibitors

Five Prime, GlaxoSmithKline present novel neighbor of punc e11 polypeptides

Actelion studies ACT-709478 in patients with photosensitive epilepsy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...